Zurich — Novartis has won a US federal court order preventing rival generic makers from selling versions of the Swiss drugmaker’s top-selling multiple sclerosis medicine Gilenya in the US, at least until a patent dispute is resolved.

Novartis had asked for a preliminary injunction to halt generics makers including Dr Reddy’s Laboratories, Mylan Pharmaceuticals, Torrent Pharma and Aurobindo Pharma, among others, from making or selling a Gilenya copy in the US until a final decision on a Novartis patent for the medicine.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now